These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 10409398

  • 21. Reduction of doxorubicin resistance by tetrandrine and dauricine in harringtonine-resistant human leukemia (HL60) cells.
    He QY, Meng FH, Zhang HQ.
    Zhongguo Yao Li Xue Bao; 1996 Mar; 17(2):179-81. PubMed ID: 9772674
    [Abstract] [Full Text] [Related]

  • 22. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
    Veronese FM, Schiavon O, Pasut G, Mendichi R, Andersson L, Tsirk A, Ford J, Wu G, Kneller S, Davies J, Duncan R.
    Bioconjug Chem; 2005 Mar; 16(4):775-84. PubMed ID: 16029018
    [Abstract] [Full Text] [Related]

  • 23. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
    Mamidipudi V, Shi T, Brady H, Surapaneni S, Chopra R, Aukerman SL, Heise C, Sung V.
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
    [Abstract] [Full Text] [Related]

  • 24. [Effects of anthracycline drugs (aclarubicin, daunorubicin, doxorubicin, epirubicin, pirarubicin) on mouse acute toxicity and rat liver microsomal lipid peroxidation].
    Shinozawa S, Gomita Y, Araki Y.
    Gan To Kagaku Ryoho; 1992 Jun; 19(6):805-9. PubMed ID: 1605657
    [Abstract] [Full Text] [Related]

  • 25. [Up-regulation of c-myc expression in MCF-7/Adr human breast cancer cells and its association with resistance against doxorubicin].
    Chen J, Yuan YW, Zhang JR, Zhou DY.
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Feb; 22(2):124-6. PubMed ID: 12390804
    [Abstract] [Full Text] [Related]

  • 26. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
    Park SJ, Wu CH, Safa AR.
    Anticancer Res; 2004 Feb; 24(1):123-31. PubMed ID: 15015586
    [Abstract] [Full Text] [Related]

  • 27. Can cytotoxic activity of anthracyclines be related to DNA damage?
    Nishiyama M, Horichi N, Mazouzi Z, Bungo M, Saijo N, Tapiero H.
    Anticancer Drug Des; 1990 Feb; 5(1):135-9. PubMed ID: 2317255
    [Abstract] [Full Text] [Related]

  • 28. Improving the cytometric detection of doxorubicin resistance in osteosarcoma cells by determining cellular doxorubicin/DNA ratio.
    Takeshita H, Kusuzaki K, Murata H, Nakamura S, Ashihara T, Hirasawa Y.
    Anticancer Res; 1999 Feb; 19(6B):5235-8. PubMed ID: 10697541
    [Abstract] [Full Text] [Related]

  • 29. Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin.
    Taatjes DJ, Gaudiano G, Resing K, Koch TH.
    J Med Chem; 1997 Apr 11; 40(8):1276-86. PubMed ID: 9111302
    [Abstract] [Full Text] [Related]

  • 30. [Intracellular accumulation, retention, and distribution of anthracyclines in a multidrug-resistant variant K562r].
    Hu X, Chen WY.
    Zhongguo Yao Li Xue Bao; 1994 May 11; 15(3):275-9. PubMed ID: 7976387
    [Abstract] [Full Text] [Related]

  • 31. Structure-based design of a new bisintercalating anthracycline antibiotic.
    Chaires JB, Leng F, Przewloka T, Fokt I, Ling YH, Perez-Soler R, Priebe W.
    J Med Chem; 1997 Jan 31; 40(3):261-6. PubMed ID: 9022792
    [Abstract] [Full Text] [Related]

  • 32. Effects of 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin and doxorubicin on the survival, DNA integrity, and nucleolar morphology of human leukemia cells in vitro.
    Wassermann K, Zwelling LA, Mullins TD, Silberman LE, Andersson BS, Bakic M, Acton EM, Newman RA.
    Cancer Res; 1986 Aug 31; 46(8):4041-6. PubMed ID: 3731072
    [Abstract] [Full Text] [Related]

  • 33. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes.
    Ling YH, Priebe W, Yang LY, Burke TG, Pommier Y, Perez-Soler R.
    Cancer Res; 1993 Apr 01; 53(7):1583-9. PubMed ID: 8453627
    [Abstract] [Full Text] [Related]

  • 34. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin.
    Wu XX, Mizutani Y, Kakehi Y, Yoshida O, Ogawa O.
    Cancer Res; 2000 Jun 01; 60(11):2912-8. PubMed ID: 10850437
    [Abstract] [Full Text] [Related]

  • 35. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines.
    Crawford KW, Bowen WD.
    Cancer Res; 2002 Jan 01; 62(1):313-22. PubMed ID: 11782394
    [Abstract] [Full Text] [Related]

  • 36. Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump.
    Priebe W, Krawczyk M, Kuo MT, Yamane Y, Savaraj N, Ishikawa T.
    Biochem Biophys Res Commun; 1998 Jun 29; 247(3):859-63. PubMed ID: 9647783
    [Abstract] [Full Text] [Related]

  • 37. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX, Yang XH.
    Yao Xue Xue Bao; 2008 May 29; 43(5):461-6. PubMed ID: 18717331
    [Abstract] [Full Text] [Related]

  • 38. Influence of the structure of new anthracycline antibiotics on their biological properties.
    Wasowska M, Oszczapowicz I, Wietrzyk J, Opolski A, Madej J, Dzimira S, Oszczapowicz J.
    Anticancer Res; 2005 May 29; 25(3B):2043-8. PubMed ID: 16158943
    [Abstract] [Full Text] [Related]

  • 39. Spectroscopic and cytotoxicity studies on the combined interaction of (-)-epigallocatechin-3-gallate and anthracycline drugs with human serum albumin.
    Guo Q, Liu M, Zhao Y, Wu Y, Liu J, Cai C, Shi Y, Han J.
    Spectrochim Acta A Mol Biomol Spectrosc; 2019 Nov 05; 222():117213. PubMed ID: 31177010
    [Abstract] [Full Text] [Related]

  • 40. Monitoring the subcellular localization of doxorubicin in CHO-K1 using MEKC-LIF: liposomal carrier for enhanced drug delivery.
    Ho JA, Fan NC, Jou AF, Wu LC, Sun TP.
    Talanta; 2012 Sep 15; 99():683-8. PubMed ID: 22967611
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.